LY-404,039

LY-404,039
(IUPAC) ime
	(-)-(1R,4S,5S,6S)-4-amino-2-sulfonilbiciklo[3.1.0]heksan-4,6-dikarboksilna kiselina
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	9834591
Hemijski podaci
Formula	C7H9NO6S
Mol. masa	235,214 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12) ; Key: AVDUGNCTZRCAHH-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

LY-404,039 je lek koji se koristi u naučnim istraživanjima kao selektivni agonist metabotropnih glutamatnih receptora grupe II podtipova mGluR₂ i mGluR₃.^[3] Istraživanja su pokazala da ima znatan afinitet (Ki = 8.2±1nM) za D₂ receptor iz čega sledi mogući mehanizam dejstva.^[4] On ima anksiolitičko i antipsihotičko dejstvo u životinjskim studijama, ali ne uzrokuje sedaciju.^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD (April 2007). „Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)”. The Journal of Pharmacology and Experimental Therapeutics 321 (1): 308–17. DOI:10.1124/jpet.106.110809. PMID 17204749.
↑ Philip Seeman, Hong-Chang Gua (2009). „Glutamate Agonist LY404,039 for Treating Schizophrenia Has Afﬁnity for the Dopamine D2 High Receptor”. SYNAPSE: 935–939. DOI:10.1002/syn.20704. Arhivirano iz originala na datum 2011-10-16. Pristupljeno 2014-04-05.
↑ Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD (July 2007). „In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders”. Psychopharmacology 193 (1): 121–36. DOI:10.1007/s00213-007-0758-3. PMID 17384937.

Povezano

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid17204749-3] Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD (April 2007). „Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)”. The Journal of Pharmacology and Experimental Therapeutics 321 (1): 308–17. DOI:10.1124/jpet.106.110809. PMID 17204749.

[4] Philip Seeman, Hong-Chang Gua (2009). „Glutamate Agonist LY404,039 for Treating Schizophrenia Has Afﬁnity for the Dopamine D2 High Receptor”. SYNAPSE: 935–939. DOI:10.1002/syn.20704. Arhivirano iz originala na datum 2011-10-16. Pristupljeno 2014-04-05.

[pmid17384937-5] Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD (July 2007). „In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders”. Psychopharmacology 193 (1): 121–36. DOI:10.1007/s00213-007-0758-3. PMID 17384937.

[1]

[2]

[3]

[4]

[5]